AVIR Q2 2021 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$484M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M

Gross Profit

$21M34.1% margin

Operating Income

$9M14.4% margin

Net Income

$2M2.5% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-8.5%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$872M

Total Liabilities

$274M

Stockholders' Equity

$598M

Cash & Equivalents

$816M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$0	—
Gross Profit	$21M	-$8M	+365.5%
Operating Income	$9M	-$10M	+186.8%
Net Income	$2M	-$10M	+115.4%